Cell Line Development Services for Glioblastoma
Glioblastoma (GBM) has the highest incidence of brain tumors, accounting for approximately 40.49% of cases. There are relatively new therapeutic approaches, such as targeted therapy, and anti-angiogenic treatments. However, researchers need not only novel therapeutic approaches, but also the development of effective therapeutic drugs. However, there are currently only a few GBM cell lines available worldwide for drug development and basic research.
Our GBM cell line development services
The scarcity of brain tumor cell lines is a serious constraint to preclinical research compared to the wide variety of brain tumor patients in the clinical setting. Alfa Cytology offers GBM cell line development services based on our extensive experience and proven platform. The GBM cell lines we develop can either be used directly as in vitro anti-GBM drug screening models or can be used to obtain highly tumorigenic human GBM animal models by multiple passages in mammals such as immunodeficient mice. This will help our customers to establish two related anti-GBM drug screening platforms in vitro and in vivo. You can use this platform to study the pathogenesis, drug resistance, and metastasis of GBM, and then search for characteristic biomarkers of GBM pathogenesis, drug resistance, and metastasis. It is an ideal cell line for basic research and preclinical applications in human brain tumors.
Successfully developed GBM cell lines
| Cell lines |
- U-87 MG
- U-251 MG
- U251
- BT325
- A172
- U373
- LN-428
- LN-308
- LN-229
- TJ905
- SHG-44
|
Organism |
Homo sapiens (Human) |
| Tissue |
Brain |
| Morphology |
Epithelial |
| Culture properties |
Adherent |
Development flow
Cases
- Preparation of GBM animal models, especially immunodeficient mice. In vitro bulk culture and collection of human GBM cells provided by us, and subcutaneous inoculation of a certain amount of cell suspension into mammals. After a period of inoculation, tumors begin to form and grow and can pass subcutaneously in mice.
- Screening of drug candidates for the treatment of GBM. The test compounds were administered to cell models (GBM cell lines provided by us) and the proliferation inhibitory capacity of the different compounds on the cells was calculated, using either the ATP bioluminescence assay or the MTT assay to calculate the compound half-inhibitory concentration. Test compounds that inhibit cell proliferation or cause apoptosis after administration were considered candidates for the treatment of human GBM.
Case Study - U-251 MG Xenograft Model
Model Introduction
The U-251 MG xenograft model offers a well-characterized preclinical platform for investigating glioblastoma multiforme (GBM) biology and evaluating the efficacy of novel therapeutic agents. U-251 MG is a human glioblastoma cell line derived from a glioblastoma astrocytoma. It is widely used in cancer research due to its characteristic GBM features, including mutated p53, PTEN loss, robust proliferative capacity, and activation of pro-survival signaling pathways such as PI3K/Akt. This model is particularly valuable for studying angiogenesis, telomerase inhibition, and combination therapies targeting DNA repair and epigenetic regulation.
Model Information
- Model: U-251 MG Xenograft Model
- Animals: Nude Mice
- Age: 9-10 Weeks
Model Construction
The model is established by subcutaneously implanting human U-251 MG glioblastoma cells into the hind leg flank of immunocompromised mice. Cell inoculum is 1×106 cells/mouse in 50% Matrigel solution. Tumor growth is monitored by palpation tri-weekly until tumors reach 100-150 mm3, at which point treatment is initiated.
Fig. 1 Workflow of U-251 MG xenograft model establishment. (Source: Alfa Cytology)
Model Data
- Tumorigenicity: U-251 MG cells demonstrate consistent and reproducible tumor formation in immunocompromised mouse strains, with high engraftment rates.
- Growth Kinetics: Tumor growth is progressive and measurable. Upon reaching 100-150 mm3, tumors provide a defined therapeutic window for assessing treatment efficacy.
Fig. 2 Representative tumor growth curves of U-251 MG subcutaneous xenograft model. Data are presented as mean ± standard error (SEM). (Source: Alfa Cytology)
The GBM cells developed by Alfa Cytology are stable in their traits and can be stably passaged multiple times. This provides new experimental material for brain tumor research that more closely resembles the biological properties of clinical brain tumors. Please contact our staff for more information on our GBM cell lines developed based on the genetic backgrounds of different populations.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
